Attovia Begins Phase 1 Trial of ATTO-1310 for Chronic Pruritus Treatment

Attovia Therapeutics, a clinical-stage biotechnology company developing treatments for immune-mediated diseases with high unmet patient needs, announced that the first subject has been dosed in a first-in-human phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) ATTOBODY-based anti-IL-31 biotherapeutic. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic conditions such as chronic pruritus of unknown origin (CPUO). Attovia is committed to developing therapies for inflammatory and immune (I&I) diseases that bring breakthrough efficacy to underserved patient populations, as well as offering excellent safety and high convenience. ATTO-1310 has the potential to achieve a best-in-disease therapeutic profile in pruritic disease with rapid and deep relief of itch, benign safety profile, and infrequent subcutaneous dosing.

“Chronic pruritus deeply affects millions of patients in the US and beyond, and there are currently no approved treatments for conditions like CPUO. ATTO-1310 has the potential to provide life-changing relief to patients suffering from these diseases. We are working with a group of international KOLs who have spent years advocating for the development of effective treatments for these patients, and who will help us drive progress in our clinical program. Advancement of ATTO-1310 into the clinic marks an important milestone for Attovia as we become a clinical-stage company delivering innovative therapies for patients with immune-mediated diseases,” said Dr. Hubert Chen, chief medical officer of Attovia.

The phase 1 study (NCT06787586) is a randomized, double-blind, placebo-controlled, multi-part, single-ascending dose and multiple-ascending dose study to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adult volunteers and patients suffering from pruritic disease.

Following closely behind ATTO-1310, Attovia is advancing four bispecific and multispecific ATTOBODY-based programs for the treatment of immune-mediated diseases. This includes ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific that will be developed for the treatment of atopic dermatitis and other inflammatory conditions; ATTO-004, a multispecific in development for inflammatory bowel disease; and two discovery stage programs with multi-disease treatment potential.

Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY, our proprietary biologics platform, to generate first-in-class and best-in-class bispecifics and multispecifics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!